Mycophenolate mofetil - Clinical and experimental experience

Therapeutic Drug Monitoring

Volumn 18, Issue 4, 1996, Pages 357-361

  Pirsch, John D ^a,b   Sollinger, Hans W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

Author keywords

Adverse effects; Kidney transplantation; Mycophenolic acid; Pharmacokinetics; Rejection

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL FUNCTION; CLINICAL OBSERVATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; DRUG MONITORING; ENZYME INHIBITION; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REACTION ANALYSIS;

CLINICAL TRIALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 0029813392     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199608000-00007     Document Type: Conference Paper

References (32)

1. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 1969;223:848-50.
2. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969;113:515-24.
3. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann NY Acad Sci 1993;696:63-87.
4. Williams RH, Lively DH, DeLong DC, et al. Mycophenolic acid: antiviral and antitumor properties. J Antibiot 1968; 21:463-4.
5. Lynch WS, Roenigk HH Jr. Mycophenolic acid for psoriasis. Arch Dermatol 1977;113:1203-8.
6. Epinette WW, Parker CM, Jones EL, Greist MC. Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy, and safety. J Am Acad Dermatol 1987;17:962-71.
7. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993:11(suppl 8):S117-9.
8. Allison AC, Eugui EM. Mycophenolate mofetil, a rationally designed immunosuppressive drug. Clin Transplant 1993; 7:96-112.
9. Morris RE, Hoyt EG, Eugui EM, Allison AC. Prolongation of rat heart allograft survival by RS 61443. Surg Forum 1989;40:337-8.
10. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991;51:27-31.
11. Benhaim P, Anthony JP, Lin LYT, McCalmont TH, Mathes SJ. A long-term study of allogeneic rat hindlimb transplants immunosuppressed with RS-61443. Transplantation 1993; 56:911-7.
12. O'Hair DP, McManus RP, Komorowski R. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann Thorac Surg 1994;58:1311-5.
13. Platz KP, Bechstein WO, Eckhoff DE, Suzuki Y, Sollinger HW. RS-61443 reverses acute allograft rejection in dogs. Surgery 1991;110:736-41.
14. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993;268:27286-90.
15. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41:1011-7.
16. Hoffmann-LaRoche Inc. CellCept (mycophenolate mofetil capsules) package insert. Nutley: Roche Laboratories, May 1995.
17. Sollinger HW, Deierhoi MH, Beizer FO, Diethelm AG, Kauffman RS. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992;53:428-32.
18. Deierhoi MH, Sollinger HW, Diethelm AG, Beizer FO, Kauffman RS. One-year follow-up results of a phase I trial of mycophenolate mofetil (RS61443) in cadaveric renal transplantation. Transplant Proc 1993;25:693-4.
19. Sollinger HW, Beizer FO, Deierhoi MH, et al. RS-61443 (mycophenolate mofetil): a multicenter study for refractory kidney transplant rejection. Ann Surg 1992;216:513-9.
20. Klintmalm GB, Ascher NL, Busutil RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993;25:697.
21. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993;56:75-82.
22. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995;60:225-32.
23. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;345:1321-5.
24. Sollinger HW, Deierhoi MH, Beizer FO, Diethelm AG, Kauffman RS. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992;53:428-32.
25. Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. Transplant Proc 1995;27:1421-4.
26. Shaw LM, Sollinger HW, Halloran P, et al. Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit 1995;17:690-9.
27. Langman LJ, LeGatt DF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measuring IMP dehydrogenase activity. Clin Chem 1995;41:295-9.
28. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P. The incidence and impact of early rejection episodes on graft outcome in recipients of first cadaver kidney transplants. Transplantation 1992;53:323-8.
29. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994;57:857-9.
30. Steele DM, Bechstein WO, Kowalski J, et al. RS-61443 inhibits intimai hyperplasia in aortic allografts. Surg Forum 1992;43:383-5.
31. Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995;59:460-6.
32. Raisanen-Sokolowski A, Aho P, Myllarniemi M, Kallio E, Hayry P. Inhibition of early chronic rejection in rat aortic allografts by mycophenolate mofetil (RS61443). Transplant Proc 1995;27:435.